Host factors that are responsible for responsiveness to HCV therapy with Peg-IFN-α/RBV include host genetic factors, age, ethnicity, gender, cirrhosis, weight (BMI), steatosis, insulin resistance (IR), and type 2 diabetes mellitus (T2DM). Here, IFNA1 is linked to type 2 diabetes mellitus.